Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous Dosage Form and Oral Dosage Form) as a Chemo-Sensitizing Agent for Cisplatin, Carboplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer that is Platinum- and/or Taxane-Refractory or Resistant.

This early-phase trial tests the safety of Phenoxodiol, given both intravenously and orally, in women with advanced ovarian, fallopian tube, or peritoneal cancer that has not responded to standard chemotherapy. Women aged 18 and older who have already tried other treatments may be eligible. Participation involves receiving the study drug and regular monitoring.